Septicemia, access and cardiovascular disease in dialysis patients: the USRDS Wave 2 study.

BACKGROUND Microinflammation is linked to cardiovascular disease, and is highly prevalent in dialysis patients. It is logical to postulate that septicemia, a common macroinflammatory occurrence in dialysis patients, contributes to their large burden of cardiovascular disease. METHODS The Dialysis Morbidity and Mortality Wave 2 was a randomly selected prospective cohort of incident dialysis patients. Admission claims data were used to define and calculate rates of septicemia or bacteremia and cardiovascular events in those with Medicare as the primary payer. Utilizing Cox proportional hazard models we determined the association between baseline access and the development of bacteremia or sepsis, and also the association between bacteremia or sepsis episodes and subsequent cardiovascular events. RESULTS The 2358 (59%) patients with Medicare as primary payer were older and more likely to have heart failure than those with other payers, but had similar comorbidity-adjusted mortality hazards. Rates of first septicemia, bacteremia, or either condition, were 7.0, 5.9 and 10.4 events per 100-patient years, respectively. Cox regression identified initial dialysis access as the main antecedent of septicemia or bacteremia. Hazards ratios for hemodialysis with permanent catheters, temporary catheters, and grafts were 1.95 (95% CI 1.47-2.57), 1.76 (95% CI 1.29-2.41), and 1.05 (95% CI 0.82-1.35), respectively, while that for peritoneal dialysis was 0.96 (95% CI 0.75-1.23) (reference arteriovenous fistula). After adjustment for baseline factors, septicemia or bacteremia, as a time-dependent covariate, was associated with subsequent death [hazards ratio (HR) 2.33, 95% CI 1.38-2.28], myocardial infarction (HR 1.78, 95% CI 1.38-2.28), heart failure (HR 1.64, 95% CI 1.39-1.95), peripheral vascular disease (HR 1.64, 95% CI 1.34-2.0), and stroke (HR 2.04, 95% CI 1.27-3.28). CONCLUSION Septicemia appears to be an important, potentially preventable, cardiovascular risk factor in dialysis patients.

[1]  R. Hubbard,et al.  Risk of myocardial infarction and stroke after acute infection or vaccination. , 2004, The New England journal of medicine.

[2]  S. Beddhu,et al.  Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO Study. , 2003, Journal of the American Society of Nephrology : JASN.

[3]  S. Yusuf,et al.  Multiple Infections and Subsequent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study , 2003, Circulation.

[4]  R. Hotchkiss,et al.  The pathophysiology and treatment of sepsis. , 2003, The New England journal of medicine.

[5]  S. Blankenberg,et al.  Impact of Infectious Burden on Progression of Carotid Atherosclerosis , 2002, Stroke.

[6]  N. Levin,et al.  Serum markers of periodontal disease status and inflammation in hemodialysis patients. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  Patrick S Romano,et al.  Can Administrative Data Be Used to Compare Postoperative Complication Rates Across Hospitals? , 2002, Medical care.

[8]  David W. Johnson,et al.  A randomized controlled trial of topical exit site mupirocin application in patients with tunnelled, cuffed haemodialysis catheters. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  J. Tokars,et al.  New national surveillance system for hemodialysis-associated infections: initial results. , 2002, American journal of infection control.

[10]  W. McClellan,et al.  Vascular access and increased risk of death among hemodialysis patients. , 2002, Kidney international.

[11]  A. Saxena,et al.  Outcome of Dialysis Access-Related Septicemia among Diabetics following Optimized AV-Fistula Placement , 2002, Kidney and Blood Pressure Research.

[12]  L. Agodoa,et al.  Hospitalizations for bacterial septicemia in patients with end stage renal disease due to diabetes on the renal transplant waiting list. , 2002, JN. Journal of Nephrology (Milano. 1992).

[13]  P. Libby,et al.  Inflammation and Atherosclerosis , 2002, Circulation.

[14]  Jein-Wei Liu,et al.  Nosocomial blood-stream infection in patients with end-stage renal disease: excess length of hospital stay, extra cost and attributable mortality. , 2002, The Journal of hospital infection.

[15]  K. Stevenson,et al.  Epidemiology of hemodialysis vascular access infections from longitudinal infection surveillance data: predicting the impact of NKF-DOQI clinical practice guidelines for vascular access. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  A. M. Fendrick,et al.  Is sepsis accurately coded on hospital bills? , 2002, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[17]  S. Black,et al.  Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. , 2002, The New England journal of medicine.

[18]  A. Saxena,et al.  THE IMPACT OF NASAL CARRIAGE OF METHICILLIN-RESISTANT AND METHICILLIN-SUSCEPTIBLE STAPHYLOCOCCUS AUREUS (MRSA & MSSA) ON VASCULAR ACCESS-RELATED SEPTICEMIA AMONG PATIENTS WITH TYPE-II DIABETES ON DIALYSIS , 2002, Renal failure.

[19]  E W Young,et al.  Type of vascular access and mortality in U.S. hemodialysis patients. , 2001, Kidney international.

[20]  G. Nassar,et al.  Infectious complications of the hemodialysis access. , 2001, Kidney international.

[21]  J. Tokars,et al.  A prospective study of vascular access infections at seven outpatient hemodialysis centers. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  B. Horne,et al.  Prospective Study of Pathogen Burden and Risk of Myocardial Infarction or Death , 2001, Circulation.

[23]  B. Di Iorio,et al.  Successful Use of Central Venous Catheter as Permanent Hemodialysis Access: 84-Month Follow-Up in Lucania , 2000, Blood Purification.

[24]  P. Stenvinkel Inflammatory and Atherosclerotic Interactions in the Depleted Uremic Patient , 2000, Blood Purification.

[25]  B. Jaber,et al.  Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. , 2000, Kidney international.

[26]  M. Rocco,et al.  Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. , 2000, Kidney international.

[27]  W. Schaffner,et al.  Hospital-acquired infections among chronic hemodialysis patients. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  F. Locatelli,et al.  Treatment modalities in comparison: when do clinical differences emerge? , 2000, Nephrology, Dialysis and Transplantation.

[29]  G. Kaysen,et al.  C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  A. Quyyumi,et al.  Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. , 2000, The American journal of cardiology.

[31]  N. Powe,et al.  Septicemia in dialysis patients: incidence, risk factors, and prognosis. , 1999, Kidney international.

[32]  C. Wanner,et al.  Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. , 1999, Kidney international.

[33]  D. Sheikh-Hamad,et al.  Silent infection in clotted hemodialysis access grafts. , 1998, Journal of the American Society of Nephrology : JASN.

[34]  Seoung Woo Lee,et al.  Serum C-Reactive Protein: A Predictor of Mortality in Continuous Ambulatory Peritoneal Dialysis Patients , 1998, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[35]  I. Raad,et al.  Intravascular-catheter-related infections , 1998, The Lancet.

[36]  R. Mactier,et al.  Long-term vascular access for hemodialysis using silicon dual-lumen catheters with guidewire replacement of catheters for technique salvage. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[37]  R. Wolfe,et al.  Relationship of dose of hemodialysis and cause-specific mortality. , 1996, Kidney international.

[38]  E. Anaissie,et al.  Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. , 1993, The Journal of infectious diseases.

[39]  M. Cirillo,et al.  Vascular access for hemodialysis: the impact on morbidity and mortality. , 2004, Journal of nephrology.

[40]  B. Gillespie,et al.  Creation, cannulation and survival of arteriovenous fistulae: data from the Dialysis Outcomes and Practice Patterns Study. , 2003, Kidney international.

[41]  J. Hux,et al.  Hemodialysis infection prevention with polysporin ointment. , 2003, Journal of the American Society of Nephrology : JASN.

[42]  S. Blankenberg,et al.  Impact of Infectious Burden on Extent and Long-Term Prognosis of Atherosclerosis , 2002, Circulation.